AIHTA - Publications - Search - Amivantamab (Rybrevant®) in combination with carboplatin and pemetrexed for the treatment of advanced non-small cell lung cancer (NSCLC)

Rothschedl, E. and Grössmann, N. (2024): Amivantamab (Rybrevant®) in combination with carboplatin and pemetrexed for the treatment of advanced non-small cell lung cancer (NSCLC). Fact Sheet Nr. 189.

[thumbnail of Fact Sheet Nr.189.pdf]
Preview
 PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
135kB

Item Type:Horizon Scanning of Medicines
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WB Practice of medicine > WB 300-962 Therapeutics
WF Respiratory system
Language:English
Series Name:Fact Sheet Nr. 189
Deposited on:24 Sep 2024 10:50
Last Modified:10 Jul 2025 11:38

Repository Staff Only: item control page